WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002006520) METHOD OF SCREENING COMPOUND CONTROLLING MEK/ERK SIGNAL TRANSDUCTION AND MEDICINAL USE OF THE COMPOUND
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/006520    International Application No.:    PCT/JP2001/006171
Publication Date: 24.01.2002 International Filing Date: 17.07.2001
Chapter 2 Demand Filed:    17.07.2001    
IPC:
C12Q 1/48 (2006.01)
Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA [JP/JP]; 5-1, Ukima 5-chome Kita-ku Tokyo 115-8543 (JP) (For All Designated States Except US).
NEZU, Jun-ichi [JP/JP]; (JP) (For US Only).
MIZUNO, Takakazu [JP/JP]; (JP) (For US Only).
OSE, Asuka [JP/JP]; (JP) (For US Only)
Inventors: NEZU, Jun-ichi; (JP).
MIZUNO, Takakazu; (JP).
OSE, Asuka; (JP)
Agent: SHIMIZU, Hatsushi; Kantetsu Tsukuba Bldg. 6F 1-1-1, Oroshi-machi Tsuchiura-shi, Ibaraki 300-0847 (JP)
Priority Data:
2000-223892 19.07.2000 JP
Title (EN) METHOD OF SCREENING COMPOUND CONTROLLING MEK/ERK SIGNAL TRANSDUCTION AND MEDICINAL USE OF THE COMPOUND
(FR) METHODE DE CRIBLAGE DE COMPOSE REGULANT LA TRANSDUCTION DE SIGNAUX MEK/ERK ET UTILISATION MEDICALE DUDIT COMPOSE
Abstract: front page image
(EN)It is found out that LKB1 specifically inhibits the Ras/MEK/ERK signal transduction pathway. It is suggested that this inhibition is caused by the action of LKB1 on the dowstream of MEK1 in the above signal transduction pathway and, therefore, depends on the kinase activity of LKB1. Based on these facts, it is possible to develop drugs control the MEK/ERK signal by using LKB1 as a target. These drugs are usable in treating various diseases including PJS in which the MEK/ERK signal participates.
(FR)Selon la présente invention, LKB1 inhibe spécifiquement la voie de transduction de signaux Ras/MEK (protéine kinase activée par mitogène)/ERK (kinase régulée par signaux extracellulaires). On suggère que cette inhibition est occasionnée par l'action de LKB1 sur la partie en aval de MEK1 dans la voie de transduction de signaux susmentionnée, et qu'elle dépend donc de l'activité de la kinase de LKB1. A partir de ces faits, on peut développer des médicaments qui régulent le signal MEK/ERK en utilisant LKB1 comme cible. On peut utiliser ces médicaments dans le traitement de diverses maladies, notamment PJS dans laquelle le signal ERK/MEK rentre en jeu.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)